Literature DB >> 19850631

Preliminary proficiency testing results for succinylacetone in dried blood spots for newborn screening for tyrosinemia type I.

Barbara W Adam1, Timothy H Lim, Elizabeth M Hall, W Harry Hannon.   

Abstract

BACKGROUND: Succinylacetone (SUAC) is the primary metabolite accumulated in tyrosinemia type I--an inborn error of metabolism that, if untreated, can cause death from liver failure during the first months of life. Newborn screening laboratories measure SUAC in dried blood spot (DBS) samples to detect asymptomatic tyrosinemia type I. We used panels of SUAC-enriched DBSs to compare and evaluate the performance of these screening tests.
METHODS: We prepared sets of DBS materials enriched with predetermined SUAC concentrations and distributed samples of these materials, along with a screening practices questionnaire, to laboratories that perform SUAC tests. We compared their reported SUAC concentrations and questionnaire responses to identify screening practices that affect SUAC test outcomes.
RESULTS: Data from 2 pilot surveys showed large differences among laboratories in SUAC recoveries, reproducible within-laboratory recoveries, and stable performance of the DBS materials. Results from 257 proficiency test analyses contained a total of 6 false-negative misclassifications. Reported recoveries of added SUAC ranged from 0 to >200%. Low-biased SUAC recoveries were associated with 1 method used by 5 laboratories. All laboratories that reported SUAC recoveries > or =100% used DBS matrix calibrators.
CONCLUSIONS: The wide ranges of SUAC concentrations reported for pilot and proficiency testing specimens demonstrate a need to harmonize quantitative results among laboratories. Although DBS matrix calibrators are important for optimizing SUAC recoveries, the preparation of these calibrators is not standardized among laboratories. Certified DBS-based SUAC calibrators are needed for accuracy and harmonization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19850631     DOI: 10.1373/clinchem.2009.133819

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  Newborn Screening for Tyrosinemia Type I: Further Evidence that Succinylacetone Determination on Blood Spot Is Essential.

Authors:  Giancarlo la Marca; Sabrina Malvagia; Elisabetta Pasquini; Catia Cavicchi; Amelia Morrone; Federica Ciani; Silvia Funghini; Fabio Villanelli; Enrico Zammarchi; Renzo Guerrini
Journal:  JIMD Rep       Date:  2011-06-22

2.  Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.

Authors:  Víctor R De Jesús; Barbara W Adam; Daniel Mandel; Carla D Cuthbert; Dietrich Matern
Journal:  Mol Genet Metab       Date:  2014-07-17       Impact factor: 4.797

3.  Metabolomic profiling suggests systemic signatures of premature aging induced by Hutchinson-Gilford progeria syndrome.

Authors:  Gustavo Monnerat; Geisa Paulino Caprini Evaristo; Joseph Albert Medeiros Evaristo; Caleb Guedes Miranda Dos Santos; Gabriel Carneiro; Leonardo Maciel; Vânia Oliveira Carvalho; Fábio César Sousa Nogueira; Gilberto Barbosa Domont; Antonio Carlos Campos de Carvalho
Journal:  Metabolomics       Date:  2019-06-28       Impact factor: 4.290

4.  Performance of succinylacetone assays and their associated proficiency testing outcomes.

Authors:  B W Adam; E M Hall; N K Meredith; T H Lim; C A Haynes; V R De Jesus; W H Hannon
Journal:  Clin Biochem       Date:  2012-08-11       Impact factor: 3.281

Review 5.  Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.

Authors:  Chris Stinton; Julia Geppert; Karoline Freeman; Aileen Clarke; Samantha Johnson; Hannah Fraser; Paul Sutcliffe; Sian Taylor-Phillips
Journal:  Orphanet J Rare Dis       Date:  2017-03-09       Impact factor: 4.123

Review 6.  Use of Dried Blood Spot Specimens to Monitor Patients with Inherited Metabolic Disorders.

Authors:  Stuart J Moat; Roanna S George; Rachel S Carling
Journal:  Int J Neonatal Screen       Date:  2020-03-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.